TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01857869

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK257049 Dosage 1
Description: RTS,S/AS01B administered as 0.5 mL dose at 0 and 1 months and 0.1 mL dose at 7 months for 0,1,7 M Group (delayed fractional dose group). In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: GSK257049 Dosage 2
Description: RTS,S/AS01B administered as three doses of 0.5mL given one month apart (0, 1, 2 M group) in the challenge model. In subjects unprotected in the first challenge, to receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge. In subjects protected in the first challenge, randomization to receive or not receive a booster with a fractional dose of RTS,S/AS01B followed by rechallenge.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Sporozoite-infected mosquitoes challenge
Description: Mosquitoes infected approximately 2-3 weeks earlier that are likely to contain sporozoites in their salivary glands will be allowed to feed on the volunteers. For each volunteer, five mosquitoes will be allowed to feed over five minutes, after which they will be dissected to confirm how many were infected, and the salivary glands scored.~The challenge is scheduled to occur approximately 21 days (3 weeks) after the last vaccination visit (Study Day 196). Volunteers who reconsent for the boost/rechallenge phase will be rechallenged with sporozoite-infected mosquitoes, scheduled to occur approximately 21 days (3 weeks) after the booster dose (Booster Phase Study Day 21).
Study: NCT02882295

Intervention type: OTHER
Intervention: Validation of a handwriting scale

Intervention type: OTHER
Intervention: Validation of a handwriting scale
Study: NCT02164656

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: mindfulness for smokers
Study: NCT02475655

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib
Description: 10 mg orally twice daily for 5 weeks
Study: NCT01972893

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZYD1
Description: Plan I - Tablet ZYD1 - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.~Plan II - Tablet ZYD1 - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.~Plan III - Tablet ZYD1 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Plan I - Tablet Placebo - 0.5, 1 , 2, 5, 10, 25 and 50 mg subcutaneously OD after overnight fasting.~Plan II - Tablet Placebo - 0.5, 1 , 2, 5, 10 and 25 mg subcutaneously OD after overnight fasting.~Plan III - Tablet Placebo 2/5 mg subcutaneously OD after overnight fasting depending on results of Plan I.
Study: NCT03382847

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Transplant with HCV positive donor, followed by surveillance and treatment of viremia
Description: Heart transplant with HCV positive donor, followed by treatment for viremia if viremia occurs
Study: NCT02061254

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cutometer
Description: 3 measures by cutometer on each area: the mean value will be the final value

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High resolution ultrasonography (echography)
Description: Cutaneous echography on the 3 areas, in order to measure skin thickness and echogenicity Measures are blinded to cutometer (by a different investigator)

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Elastography
Description: 10 measures on the 3 areas (central measures will be doubled) Measures will be performed blinded to cutometer

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin biopsy
Description: Skin biopsy of 3 mm in diameter, for 30 participants, to evaluate histological fibrosis
Study: NCT03371797

Intervention type: DRUG
Intervention: Valsartan, Amlodipine -
Description: Valsartan is a non-peptide, orally active, and specific angiotensin II receptor blocker acting on the AT1 receptor subtype used as an antihypertensive agent.~Amlodipine besylate is a dihydropyridine long-acting calcium channel blocker.
Study: NCT03130790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varlitinib
Description: 300mg, oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX6
Description: concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets, twice daily for 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: mFOLFOX6
Description: concurrent oxaliplatin 85 mg/m2 and leucovorin 400 mg/m2 IV in 500 ml 5% dextrose water (D5W) over 120 minutes on Day 1; then 5 Fluorouracil bolus 400 mg/m2 IV on Day 1 followed by continuous infusion 2400 mg/ m2 over 46 hours starting on Day 1) every 2 weeks. Number of cycles: until disease progression, unacceptable toxicity, withdrawal of consent, or death.
Study: NCT02893579

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Early SR intervention
Description: Self-directed stress reduction program delivered through a smart-phone application

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed SR intervention
Description: Activity tracking only for the first month
Study: NCT01256190

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Fibrocaps (fibrin sealant)
Description: human thrombin and fibrinogen topical powder

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Gelatin sponge
Description: absorbable gelatin sponge for topical use

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gelatin sponge
Description: absorbable gelatin sponge for topical use
Study: NCT02936661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00659347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: DOV 21, 947
Description: Capsules, 25 mg, 2 capsules (1 Active/1 Placebo) BID, 2 weeks Capsules, 25 mg, 2 capsules (2 Active) BID, 2 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsules,25 mg,BID,6weeks
Study: NCT03596541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heart and Respiratory Auscultation of an open real-time tele-stethoscopy system (EHAS-Fundatel digital stethoscope)
Description: We compare the respiratory and heart auscultation of clinicians using the EHAS-Fundatel digital stethoscope and a conventional stethoscope and we will observe; inter-observer and intra-observer differences by two auscultation methods.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Heart and Respiratory Auscultation of an open real-time tele-stethoscopy system (EHAS-Fundatel digital stethoscope)
Description: We compare the respiratory and heart auscultation of clinicians using the EHAS-Fundatel digital stethoscope and a conventional stethoscope and we will observe; inter-observer and intra-observer differences by two auscultation methods.
Study: NCT02065427

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social Support
Description: a) PHCT professionals: standardized training to implement caregivers intervention. b) Caregivers: 1 individualized counselling session, 1 family session, and 4 educational group sessions conducted by participating PHCT professionals; in addition to usual home health care visits, periodic telephone follow-up contact and unlimited telephone support.
Study: NCT04328207

Intervention type: OTHER
Group type: OTHER
Intervention: No Financial Incentive
Description: Standard of care eye health education

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial Incentive
Description: Patients who are referred for an in-person follow-up exam will receive a financial incentive once the referral visit is completed.
Study: NCT02855541

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DeskCycle
Description: A small cycling ergometer that can fit under a desk at the workplace.
Study: NCT02482675

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose
Description: Following baseline measurements, participants will consume a 75 g glucose solution within five minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose with Non-fat Milk
Description: Following baseline measurements, participants will consume 75 g glucose dissolved in two cups of non-fat milk within five minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose with Whey Protein Isolate
Description: Following baseline measurements, participants will consume 75 g glucose and whey protein isolate dissolved in 2 cups water within five minutes.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glucose with Sodium Caseinate
Description: Following baseline measurements, participants will consume 75 g glucose and sodium caseinate dissolved in 2 cups water within five minutes.
Study: NCT02217566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abiraterone acetate
Description: Participants will receive abiraterone acetate 1000 mg (4\*250 mg tablets) orally once daily until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Participants will prednisone 5 mg orally once daily from Day 1 of Cycle 1 and continues until PSA progression, clinical progression, consent withdrawal, or the occurrence of unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT)
Description: Participants will remain on a stable regimen of ADT, that is, luteinizing hormone-releasing hormone (LHRH) agonists including leuprolide acetate and goserelin acetate as per Investigator's discretion.
Study: NCT03195478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Specified dose on specified days
Study: NCT01077973

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Novel Ibuprofen
Description: Single-dose of novel ibuprofen (equal to 400 mg ibuprofen) plus placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Ibuprofen
Description: Single-dose of standard ibuprofen (400mg) plus placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single-dose of placebo
Study: NCT04762628

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: MAF capsules 148 mg
Description: enteric capsules based on enzymatically treated bovine colostrum

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: M capsules 148 mg
Description: enteric capsules based on enzymatically treated bovine whey

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of care
Description: Standard of care
Study: NCT00328146

Intervention type: OTHER
Intervention: Observation of sternal reentry
Description: Observation of sternal reentry
Study: NCT04393610

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Patients will receive lidocaine 3 mg/kg total of 40 ml (control group).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulphate
Description: Patients will receive lidocaine 3 mg/kg total of 40 ml plus Magnesium sulphate 30 mg/kg maximum 1.5 gm, mixed with the second 20 ml of block solution.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Patients will receive lidocaine 3 mg/kg total of 40 ml plus fentanyl 1 mcg/kg, mixed with lidocaine given after the first 20 ml of block solution.
Study: NCT03362775

Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Description: Target-controlled infusion of propofol with an effect-site concentration of 0.0 µL/mL; 0.5 µL/mL and 1.0 µL/mL.
Study: NCT01032551

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Vascular Access Decision Aid
Description: The intervention group will receive a PtDA addressing vascular access for CA procedures. The PtDA is a brief lay summary that outlines, the purpose of the PtDA, a description of both femoral and radial approaches for CA procedures, what to expect from both approaches, the known risks/benefits of each access site (including a grading of the evidence), and a short assessment of the patients values. The values assessment is included in the PtDA as a means to help guide the patient through the decision making process. This section will ask the patient to explicitly state which features, risks, and benefits of each approach are important to them.
Study: NCT03093038

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: H-MAX stem & Delta-TT cup + polyethylene
Description: H-MAX femoral stem \& Delta-TT cup with a polyethylene insert

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: H-MAX stem & Delta-TT cup + ceramic
Description: H-MAX femoral stem \& Delta Delta-TT cup with a Ceramic insert

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: C2 stem & Delta-TT cup + ceramic
Description: C2 femoral stem Delta Delta-TT cup with a Ceramic insert
Study: NCT01750515

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture
Study: NCT00924937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mediterranean Diet
Description: Mediterranean Diet:35-38% fat (22% MUFA; 6% PUFA; \<10% SAT).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low Fat Diet
Description: Low fat diet: \<30% fat (12% MUFA; 6-8%PUFA; \<10% SAT)
Study: NCT00323557

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sargramostim (GM-CSF)
Description: Starting with 3 doses of 250 micrograms subcutaneously, either pre or post vaccine. For pre vaccine, GM-CSF on days -7 (+ 1 day) and -3 (+ 1 day), in the week prior to vaccination for pre-vaccination immune priming; 3rd dose on the day of vaccination (day 0); and for post-vaccine GM-CSF given simultaneously on day of vaccination (day 0) and 2 more doses Day +3 and Day +7 after pneumococcal vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pneumococcal Vaccine
Description: Subcutaneously on Day 0
Study: NCT00684957

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Growth Hormone
Description: 300 mcg sc qd (which may be increased to 400 mcg sc qd after 4 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human Growth Hormone
Description: 300 mcg sc qd (which may be increased to 400 mcg sc qd after 4 weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human IGF-1
Description: 30 µg/kg for first 4 weeks (may be increased thereafter based on IGF-1 levels)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant Human IGF-1
Description: 30 µg/kg for first 4 weeks (may be increased thereafter based on IGF-1 levels)
Study: NCT00684515

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar 2.5 mg
Description: Oral tablets; once daily for 60 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorapaxar 1 mg
Description: Oral tablets; once daily for 60 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral tablets; once daily for 60 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aspirin 75-150 mg
Description: oral tablets; once daily for 60 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 75-150 mg
Description: oral tablets; once daily for 60 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 75-150 mg
Description: oral tablets; once daily for 60 days
Study: NCT04389242

Intervention type: OTHER
Group type: OTHER
Intervention: REST Online（Reduce Stress Tour Online）
Description: Different cognitive behavioral skills are introduced and practiced in a 8 weekly online program, which includes animation briefing and debriefing, case demonstration video, exercise, forum, internal messaging, online assessment and reminder. One face-to-face session and one telephone follow-up provided by an experienced CBT therapist are also provided to clients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REST Online（Reduce Stress Tour Online）
Description: Different cognitive behavioral skills are introduced and practiced in a 8 weekly online program, which includes animation briefing and debriefing, case demonstration video, exercise, forum, internal messaging, online assessment and reminder. One face-to-face session and one telephone follow-up provided by an experienced CBT therapist are also provided to clients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: REST Online（Reduce Stress Tour Online）
Description: Different cognitive behavioral skills are introduced and practiced in a 8 weekly online program, which includes animation briefing and debriefing, case demonstration video, exercise, forum, internal messaging, online assessment and reminder. One face-to-face session and one telephone follow-up provided by an experienced CBT therapist are also provided to clients.
Study: NCT03244033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Contextual clinical decision support
Description: Incorporation of contextual data into EHR clinical decision support alerts

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Contextual survey
Description: Patients complete a survey asking about red flags that could signal contextual factors relevant to their care

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Contextual survey
Description: Patients complete a survey asking about red flags that could signal contextual factors relevant to their care
Study: NCT00859703

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: 35mg oral risedronate once per week for 24 months

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 35 mg once a week for 24 months
Study: NCT04507984

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic analysis
Description: After obtaining written consent from patients, DNA is isolated, and genetic analysis of the know familial hypercholesterolemia disease-causing genes (LDLR, APOB, PCSK9) is performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Genetic analysis
Description: After obtaining written consent from patients, DNA is isolated, and genetic analysis of the know familial hypercholesterolemia disease-causing genes (LDLR, APOB, PCSK9) is performed.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lipid levels measurement
Description: Measurements of lipid levels (total cholesterol, LDL-cholesterol, HDL-cholesterol, TG) using standard methods.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lipid levels measurement
Description: Measurements of lipid levels (total cholesterol, LDL-cholesterol, HDL-cholesterol, TG) using standard methods.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lipid levels measurement
Description: Measurements of lipid levels (total cholesterol, LDL-cholesterol, HDL-cholesterol, TG) using standard methods.

Intervention type: DIAGNOSTIC_TEST
Intervention: Lipid levels measurement
Description: Measurements of lipid levels (total cholesterol, LDL-cholesterol, HDL-cholesterol, TG) using standard methods.
Study: NCT00813397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sepraspray
Description: Max. 10g of Sepraspray
Study: NCT02272686

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: 560 mg by mouth daily.
Study: NCT01707615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSPE
Description: GSPE 240 mg/day (120mg bid)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lifestyle intervention
Description: dietary modification making the total ingestion of calories into standard body weight 25 kCal in effect and an individualized home exercise program of a minimum 150 min/week of moderate-intensity physical activity

Intervention type: OTHER
Group type: OTHER
Intervention: lifestyle intervention
Description: dietary modification making the total ingestion of calories into standard body weight 25 kCal in effect and an individualized home exercise program of a minimum 150 min/week of moderate-intensity physical activity
Study: NCT03085914

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat oral twice-daily continuous daily dosing at the protocol-defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat oral twice-daily continuous daily dosing at the protocol-defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat oral twice-daily continuous daily dosing at the protocol-defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat oral twice-daily continuous daily dosing at the protocol-defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat oral twice-daily continuous daily dosing at the protocol-defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat oral twice-daily continuous daily dosing at the protocol-defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epacadostat
Description: Epacadostat oral twice-daily continuous daily dosing at the protocol-defined dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab